Stockreport

Immatics Announces First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, includ [Read more]